Increased level of serum HLA class I antigens in patients with systemic lupus erythematosus. Correlation with disease activity |
| |
Authors: | A. Brescianl G. Pirozzi M. Spera M.L. Lombardi L. Ambrosone S. Migliaresi S. Ferrone C. Manzo |
| |
Affiliation: | Servizio di Oncologia Sperimentale C-lmmunologia, Istttuto Tumori Fondaztone Pascale;Clinica Medica, Reumatologia, Seconda Universitàdegll Studi di Napoli, Napoll, Italy;Department of Microbiology &Immunology, New York Medical College, Valhalla, NY, USA |
| |
Abstract: | Abstract: The level of soluble pYn-assoriated HLA Class I heavy chains (sHLA-I) and of soluble β2-μ-free HLA Class I heavy chains (sHLA-FHC) was found to be significantly higher in sera from 58 patients with systemic lupus erythematosus (SLE) than in those from 82 age and sex-matched controls. The level of serum sHLA-I in patients with SLE was significantly correlated to disease activity. Western blotting analysis showed that the 44-kDa isoform represents the major component in the antigens immuno-precipitated by anti-β2-μ mAb NAMB-1 and by anti-β2-μ-free HLA Class I heavy chain mAb HC-10 from sera of patients with SLE. These results suggest that the increased serum levels of sHLA-I and of sHLA-FHC in patients with SLE reflect their increased shedding from cell membrane. In view of the ability of sHLA-I and of sHLA-FHC to induce apoptosis of activated T cells, it is suggested that their increased serum levels in patients with SLE is triggered by dysregulation of the immune system leading to T-cell activation. The increased serum levels of sHLA-I and of sHLA-FHC may be used by the immune system to control the pool of activated T cells by inducing apoptosis. If this possibility is proven to be correct, modulation of the serum level of sHLA-I and of sHLA-FHC may be utilized to develop strategies to treat SLE. |
| |
Keywords: | double determinant immunoassay serum HLA-I serum β2-μ-free HLA-1 heavy chain systemic iupus erythematosus Western blot |
|
|